We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.16% | 123.00 | 122.20 | 122.80 | 124.00 | 122.20 | 122.60 | 632,316 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.55 | 814.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/8/2018 12:24 | Biggest riser in the FTSE250 | volsung | |
29/8/2018 11:55 | Syncona on the up today. Autolus appears to be up around the $30 mark and Nightstar doing well. I considered buying at 120p when this was BACIT but delayed and only got in at 165p a few months ago. Still good profit not to be sniffed at. There is a very good analysis of Nightstar on www.seekingalpha.com Conclusions of the article “ Conclusion Nightstar Therapeutics is a promising preclinical biotechnology company focused on gene therapies for the treatment of currently untreatable genetic retinal diseases. Its pipeline so far has shown promising results, with its trial structure providing potential 'downside protection' in case of subpar news for its Phase 3 STAR trial. Additionally, it offers an attractive combination of strong balance sheet (almost entirely cash with no debt), institutional investors with a long-term investment view, and limited cash burn. A potential funding gap that might arise around 2020 should also offer no issue, as the company could either easily return to the capital markets or outlicense the rights to either of its therapies. Most notably, however, is the potential for the stock in September: Not only is it providing investors with data on its second product candidate, but could also deliver a positive surprise with additional data at its R&D Day.“ | brexitplus | |
29/8/2018 10:41 | Cheers David. Nice to see | volsung | |
29/8/2018 10:40 | WTF? Good timing volsung… :-) DL | davidlloyd | |
24/8/2018 10:03 | Like the look of SYNC. Bought a small initial stake this morning | volsung | |
23/8/2018 16:59 | Bouncing indeed! | audigger | |
23/8/2018 11:21 | Naw it's bouncing back up now | luxaeterna1 | |
22/8/2018 17:39 | It looks like 250 may come tomorrow unless it bounces. I almost sold on the previous high of 282 but didn't and it pulled back sharply only to quickly recover. I wonder if this pattern will repeat itself? | audigger | |
22/8/2018 16:46 | I will top up at 250 or there abouts. Would really like to know the identity of the new investment. | brexitplus | |
22/8/2018 09:27 | Ah, so you're the culprit then, AuD. Congratulations on your timing. | alan@bj | |
22/8/2018 08:27 | I sold at 297. I'd set 300 as my target but decided 297 was good enough after buying in at 160-170. I intend to get back in at 250 but there's a risk it may not pull back that far. | audigger | |
22/8/2018 07:39 | The Times business section comments that Syncona's 5.7% fall yesterday was "Investors cashing in after recent strong run." | alan@bj | |
22/8/2018 07:02 | Acuere.I agree entirely with your post regarding your future valuation thoughts.LT | ltinvestor | |
21/8/2018 14:54 | Autolus and Nightstar both on an upward trend. | brexitplus | |
21/8/2018 14:09 | Nah, it just hit £3, more of a natural human resistance barrier and pinged back a bit. Quite natural. Always a chance there's something else in the background, but I saw it hit £3 and thought it would pull back. Trend still seems upwards but will need to drop to get support and move forward from there. | luxaeterna1 | |
21/8/2018 11:08 | Profit taking? | brexitplus | |
20/8/2018 18:31 | Synopsis of the above mentioned report, but I see it was published a few months ago. | rambutan2 | |
20/8/2018 18:10 | I’ve had a look and can’t find any start-ups that fit the bill of the new investment. | brexitplus | |
20/8/2018 08:48 | I was trying to see what was behind this current share price surge. Last week Autolus rose 26% and nightstar 10%. Those rises appear to be on the back of a comprehensive Gene Therapy Matket report for 2018-2030. I don’t have access to the report - too expensive - but I know that syncona and nightstar were in it. Previous reports have forecast compound annual growth in gene therapy market of 33% for next 5 years and an expected 4 billion market by 2023. I would assume the report was positive and with syncona hoping to be a dominant player it is not hard to see Syncona market cap being many multiples of current level in not too many years time. | acuere | |
20/8/2018 08:20 | Try looking at Pioneer fund on Syncona website for clues. Otherwise I have no idea. Could also google the relevant details. | brexitplus | |
20/8/2018 08:17 | Anybody have any ideas what company this could be? Snippet from the Syncona quarterly update. "In addition, Syncona made a commitment of £9.8 million[4] to a new portfolio company which uses a novel technology platform to enable the discovery of therapeutics acting at targets in the cell membrane. The technology, which has been developed by the company’s world-leading academic founder, offers the potential to address previously intractable small molecule and antibody drug targets. Syncona has a 46 per cent stake in this early stage business and has been working with the company to define its business plan and strategic direction. Further information will be provided in due course." | luxaeterna1 | |
19/8/2018 17:46 | i was referring to arix COMP for management over there, comp running at $5m yes this is the syncona BB, i think you were referring to syncona management comp | kristini2 | |
19/8/2018 16:09 | Read the annual report. Directors £219k. Previously there was a management fee but that has been brought in-House. “Revised arrangements for the management of the fund investments expected to deliver significant cost savings Towards the end of the financial year we announced revised arrangements for the management of the fund investments, including an agreement with BACIT to terminate its Investment Management Agreement (IMA) and for Arabella Cecil (former CIO of BACIT) to join SIML as Head of Fund Investments. In consideration for the significant early cessation of the IMA, Syncona paid a fee to BACIT of £3.8 million. These arrangements came into effect on 1 April 2018. They are expected to deliver significant cost savings to Syncona over the life of the original BACIT agreement and will reduce the maximum management fees incurred by the Company to 1.1 per cent of NAV per annum, from 1.19 per cent. Expenses Our ongoing charges ratio for the year was 1.01 per cent[14], and included fees paid to SIML and BACIT of £7.6 million, or 0.79 per cent of NAV. This year’s ongoing charges ratio compares to 0.72 per cent in 2017, with the increase reflecting a full year of costs associated with the management of the life science portfolio. Allowing for the costs associated with the Company’s Long-Term Incentive Plan, ongoing charges increased to 1.58 per cent (2017: 0.72 per cent). Long-Term Incentive Plan The strong performance of the life science portfolio has significantly exceeded the 15 per cent growth hurdle[15] for the Company’s Long-Term Incentive Plan (“LTIP”) | brexitplus | |
19/8/2018 15:45 | That clears that up then, you just made these figures up. I trust you are employing someone to do your research before you invest money !! | kristini2 | |
19/8/2018 08:47 | Directors take 219k. Management fee has changed, but total much less as % than Arix | brexitplus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions